PSUSA/00000411/202505
Submitted by Anonymous (not verified) on 16 January 2026 - 15:49
PSUSA/00000411/202505
PSUSA/00010226/202505
Submitted by Anonymous (not verified) on 16 January 2026 - 15:47
PSUSA/00010226/202505
PSUSA/00001128/202505
Submitted by Anonymous (not verified) on 16 January 2026 - 15:46
PSUSA/00001128/202505
PSUSA/00010651/202505
Submitted by Anonymous (not verified) on 16 January 2026 - 15:45
PSUSA/00010651/202505
PSUSA/00002642/202505
Submitted by Anonymous (not verified) on 16 January 2026 - 15:44
PSUSA/00002642/202505
PSUSA/00001939/202505
Submitted by Anonymous (not verified) on 16 January 2026 - 15:43
PSUSA/00001939/202505
PSUSA/00001371/202506
Submitted by Anonymous (not verified) on 16 January 2026 - 15:42
PSUSA/00001371/202506
PSUSA/00001898/202506
Submitted by Anonymous (not verified) on 16 January 2026 - 15:41
PSUSA/00001898/202506
Human medicines European public assessment report (EPAR): Sugammadex Adroiq, sugammadex, Date of authorisation: 26/05/2023, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 16 January 2026 - 15:36
Human medicines European public assessment report (EPAR): Sugammadex Adroiq, sugammadex, Date of authorisation: 26/05/2023, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Ervebo, Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live), Date of authorisation: 11/11/2019, Revision: 13, Status: Authorised
Submitted by Anonymous (not verified) on 16 January 2026 - 15:35
Human medicines European public assessment report (EPAR): Ervebo, Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live), Date of authorisation: 11/11/2019, Revision: 13, Status: Authorised